These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 27199430)

  • 21. Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression.
    van Gils MJ; Euler Z; Schweighardt B; Wrin T; Schuitemaker H
    AIDS; 2009 Nov; 23(18):2405-14. PubMed ID: 19770692
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bystander CD4 T-cell death is inhibited by broadly neutralizing anti-HIV antibodies only at levels blocking cell-to-cell viral transmission.
    Luo X; Mouquet H; Schwartz O; Greene WC
    J Biol Chem; 2021 Oct; 297(4):101098. PubMed ID: 34418431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of replication of primary HIV-1 isolates in huPBL-NOD/Scid mice by antibodies from HIV-1 infected patients.
    Steyaert S; Heyndrickx L; Verhoye L; Vermoesen T; Donners H; Fransen K; Van Wanzeele F; Vandergucht B; Vanham G; Leroux-Roels G; Vanlandschoot P
    Antiviral Res; 2007 Aug; 75(2):129-38. PubMed ID: 17379323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine Design.
    Sadanand S; Suscovich TJ; Alter G
    Annu Rev Med; 2016; 67():185-200. PubMed ID: 26565674
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Broadly neutralizing antibody and the HIV reservoir in acute HIV infection: a strategy toward HIV remission?
    Ananworanich J; McSteen B; Robb ML
    Curr Opin HIV AIDS; 2015 May; 10(3):198-206. PubMed ID: 25700203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo protection by broadly neutralizing HIV antibodies.
    van Gils MJ; Sanders RW
    Trends Microbiol; 2014 Oct; 22(10):550-1. PubMed ID: 25169020
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Broadly neutralizing antibodies suppress HIV in the persistent viral reservoir.
    Chun TW; Murray D; Justement JS; Blazkova J; Hallahan CW; Fankuchen O; Gittens K; Benko E; Kovacs C; Moir S; Fauci AS
    Proc Natl Acad Sci U S A; 2014 Sep; 111(36):13151-6. PubMed ID: 25157148
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Focus on the therapeutic efficacy of 3BNC117 against HIV-1: In vitro studies, in vivo studies, clinical trials and challenges.
    Liu ZJ; Bai J; Liu FL; Zhang XY; Wang JZ
    Int Immunopharmacol; 2017 Nov; 52():44-50. PubMed ID: 28858725
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apoptosis of CD4+ and CD19+ cells during human immunodeficiency virus type 1 infection--correlation with clinical progression, viral load, and loss of humoral immunity.
    Samuelsson A; Broström C; van Dijk N; Sönnerborg A; Chiodi F
    Virology; 1997 Nov; 238(2):180-8. PubMed ID: 9400591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short Communication: Exploring Antibody Potential as Prophylactic/Therapeutic Strategies for Prevention of Early Mucosal HIV-1 Infection.
    Su B; Peressin M; Ducloy C; Penichon J; Mayr LM; Laumond G; Schmidt S; Decoville T; Moog C
    AIDS Res Hum Retroviruses; 2015 Nov; 31(11):1187-91. PubMed ID: 26252799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emergence of monoclonal antibody b12-resistant human immunodeficiency virus type 1 variants during natural infection in the absence of humoral or cellular immune pressure.
    Bunnik EM; van Gils MJ; Lobbrecht MS; Pisas L; Nanlohy NM; van Baarle D; van Nuenen AC; Hessell AJ; Schuitemaker H
    J Gen Virol; 2010 May; 91(Pt 5):1354-64. PubMed ID: 20053822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Immune Effects and Mechanisms of HIV-specific Antibodies Against Viral Infection].
    Su B; Li L; Mou D; Moog C; Wu H; Zhang T
    Bing Du Xue Bao; 2016 Nov; 32(6):830-8. PubMed ID: 30004659
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells.
    Sung JA; Pickeral J; Liu L; Stanfield-Oakley SA; Lam CY; Garrido C; Pollara J; LaBranche C; Bonsignori M; Moody MA; Yang Y; Parks R; Archin N; Allard B; Kirchherr J; Kuruc JD; Gay CL; Cohen MS; Ochsenbauer C; Soderberg K; Liao HX; Montefiori D; Moore P; Johnson S; Koenig S; Haynes BF; Nordstrom JL; Margolis DM; Ferrari G
    J Clin Invest; 2015 Nov; 125(11):4077-90. PubMed ID: 26413868
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dynamics of memory and naïve CD8+ T lymphocytes in humanized NOD/SCID/IL-2Rgammanull mice infected with CCR5-tropic HIV-1.
    Sato K; Nie C; Misawa N; Tanaka Y; Ito M; Koyanagi Y
    Vaccine; 2010 May; 28 Suppl 2():B32-7. PubMed ID: 20510741
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Catch Me If You Can--The Race Between HIV and Neutralizing Antibodies.
    Geiß Y; Dietrich U
    AIDS Rev; 2015; 17(2):107-13. PubMed ID: 26035168
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A constant threat for HIV: Fc-engineering to enhance broadly neutralizing antibody activity for immunotherapy of the acquired immunodeficiency syndrome.
    Nimmerjahn F
    Eur J Immunol; 2015 Aug; 45(8):2183-90. PubMed ID: 26140474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Qualitative and quantitative variables that affect the potency of Fc- mediated effector function in vitro and in vivo: considerations for passive immunization using non-neutralizing antibodies.
    Lewis GK
    Curr HIV Res; 2013 Jul; 11(5):354-64. PubMed ID: 24191940
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti-HIV-1 IgG1 antibodies in vivo.
    Wang P; Gajjar MR; Yu J; Padte NN; Gettie A; Blanchard JL; Russell-Lodrigue K; Liao LE; Perelson AS; Huang Y; Ho DD
    Proc Natl Acad Sci U S A; 2020 Jul; 117(30):18002-18009. PubMed ID: 32665438
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies.
    Trkola A; Kuster H; Rusert P; Joos B; Fischer M; Leemann C; Manrique A; Huber M; Rehr M; Oxenius A; Weber R; Stiegler G; Vcelar B; Katinger H; Aceto L; Günthard HF
    Nat Med; 2005 Jun; 11(6):615-22. PubMed ID: 15880120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.